-Emilio Bajetta Researcher Activity Profile

Research Author Detailed Information 

Emilio Bajetta Publication Rate By Year

Emilio Bajetta has published 1 paper(s) in 1974, 1 paper(s) in 1976, 1 paper(s) in 2001, 18 paper(s) in 2007, 3 paper(s) in 2008, for a total of 24 research publications in total.

Emilio E Bajetta Author Information

LAST NAME: bajetta

FIRST NAME: Emilio

INITIALS: e

AFFILIATION:

Papers

Emilio Bajetta's Publication Record

1. Impressive objective response in a patient with extensive metastatic melanoma including the brain. Year Published: 2007
Department of Medical Oncology and Radiology, Istituto Nazionale Tumori, Milan, Italy.
2. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
1Ospedale Niguarda Ca' Granda, Milan, Italy.
3. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
4. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
5. Adjuvant use of interferon alpha2b is not justified in patients with stage IIb/III melanoma. Year Published: 2007
E Bajetta is Chief of Medical Oncology, IRCCS Fondazione 'Istituto Nazionale dei Tumori', Milan, Italy.
6. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Year Published: 2007
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
7. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Year Published: 2007
Department of Medicine, Institut Gustave Roussy, Villejuif, France. escudier@igr.fr
8. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
9. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
10. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Year Published: 2007
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
11. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
12. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Year Published: 2007
Department of Medicine, Institut Gustave Roussy, Villejuif, France. escudier@igr.fr
13. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Year Published: 2007
Department of Medicine, Institut Gustave Roussy, Villejuif, France. escudier@igr.fr
14. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Year Published: 2007
Medical Oncology Unit 2, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy. emilio.bajetta@istitutotumori.mi.it
15. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
16. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Year Published: 2007
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
17. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Year Published: 2007
Ospedale Niguarda Ca' Granda, Milan, Italy. salvatore.siena@ospedaleniguarda.it
18. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Year Published: 2008
Division of Medical Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. vhess@uhbs.ch
19. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Year Published: 2008
Division of Medical Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. vhess@uhbs.ch
20. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer] Year Published: 2001
Universitäts-Frauenklinik Klinikum Innenstadt der LMU München, Germany. Harald.Sommer@fk-i.med.uni-muenchen.de
21. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Year Published: 2007
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
22. Laparoscopy and laparotomy in staging Hodgkin's and non-Hodgkin's lymphoma. Year Published: 1976
23. Methotrexate (NSC-740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix. Year Published: 1974
24. Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? Year Published: 2008
Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.